This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Sponsor
Neurona Therapeutics
Status of enrollment
Accepting new patients
Ages Eligible for Study
Adults aged 18-75 years
Genders Eligible for Study
Female and Male
Disease indication
Epilepsy - Bilateral Temporal Focal Seizures
Principal Investigator
Robert Knowlton MD
Contact
Robert Knowlton MD
Additional study eligibility details can be found at UCSF Clinical Trials.